Evidence map›Paper›PMID 29540496›Full record

ReviewEuropean respiratory review : an official journal of the European Respiratory Society2018

Exacerbations of COPD.

Christian Viniol, Claus F Vogelmeier

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European respiratory review : an official journal of the European Respiratory Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05315674 (Early Diagnostic BioMARKers in Exacerbations of COPD), which is not on this map. Cited by 159 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 7 pooled it
22.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05315674 unknown statusnot on this mapstarted 2022, after this paper: background citation

Early Diagnostic BioMARKers in Exacerbations of COPD: the MARKED Study

TypeobservationalSponsorCenter of Expertise for Chronic Organ FailureRan2022 to 2025Enrolled150ConditionsCOPD, COPD ExacerbationArmsFrequent assessment of biomarker panel
3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 7 syntheses or guidelines pooled it, 276 citations in OpenAlex.

  1. Pooled it
  2. Joint longitudinal model-based meta-analysis of FEVJournal of pharmacokinetics and pharmacodynamics · 2023
    Pooled it
  3. Inhaled corticosteroids for the treatment of COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  4. Pooled it
  5. The role of CD8 + T lymphocytes in chronic obstructive pulmonary disease: a systematic review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Sex Differences and Survival Among COPD Patients in France: The Palomb Cohort.International journal of chronic obstructive pulmonary disease · 2026
    Observational

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Christian ViniolDept of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-Universität Marburg, Member of the German Centre for Lung Research (DZL), Marburg, Germany Christian.Viniol@med.uni-marburg.de.
Claus F VogelmeierDept of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-Universität Marburg, Member of the German Centre for Lung Research (DZL), Marburg, Germany.
Philipps University of Marburg · DEUniversities of Giessen and Marburg Lung Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer from exacerbations. Severe exacerbations are related to a significantly worse survival outcome. This review summarises the current knowledge on the different aspects of COPD exacerbations. The impact of risk factors and triggers such as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections and comorbidities is discussed. More severe exacerbations should be treated with β-agonists and anticholinergics as well as systemic corticosteroids. Antibiotic therapy should only be given to patients with presumed bacterial infection. Noninvasive ventilation is indicated in patients with respiratory failure. Smoking cessation is key to prevent further COPD exacerbations. Other aspects include choice of pharmacotherapy, including bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors, long-term antibiotics and mucolytics. Better education and self-management as well as increased physical activity are important. Influenza and pneumococcal vaccination is recommended. Treatment of hypoxaemia and hypercapnia reduce the rate of COPD exacerbations, while most interventional bronchoscopic therapies increase exacerbation risk within the first months after the procedure.

Indexed as

Risk Reduction BehaviorAnti-Bacterial AgentsBronchodilator AgentsDiet, HealthyDisease ProgressionExerciseHealth Knowledge, Attitudes, PracticeHumansLungNoninvasive VentilationPatient Education as TopicPulmonary Disease, Chronic ObstructiveRisk FactorsSelf CareSmoking CessationTreatment OutcomeAnti-Bacterial AgentsBronchodilator Agents

Identifiers

PMID29540496
PMCPMC9488662
OpenAlexW2794019240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.